Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock DownZacks Investment Research • 03/06/25
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business UpdatesGlobeNewsWire • 03/05/25
Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference TranscriptSeeking Alpha • 03/03/25
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in MarchGlobeNewsWire • 02/24/25
Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)Seeking Alpha • 01/15/25
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic PrioritiesGlobeNewsWire • 01/13/25
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/25
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut WorkforceZacks Investment Research • 12/16/24
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026Benzinga • 12/13/24
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two YearsGlobeNewsWire • 12/12/24
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/09/24
Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)Seeking Alpha • 12/04/24
Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)Seeking Alpha • 11/20/24
Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to DeclineZacks Investment Research • 10/25/24
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock DownZacks Investment Research • 10/23/24
EDIT Inks Collaboration Deal to Develop Novel Gene Editing TherapiesZacks Investment Research • 10/22/24